Description: Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Home Page: www.olema.com
OLMA Technical Analysis
512 2nd Street
San Francisco,
CA
94107
United States
Phone:
650 243 5555
Officers
| Name | Title |
|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | Pres, CEO & Director |
| Mr. Shane William Charles Kovacs M.B.A. | Chief Operating & Financial Officer |
| Dr. Cyrus L. Harmon Ph.D. | Chief Research Officer & Director |
| Mr. Kinney Horn | Chief Bus. Officer |
| Dr. Peter J. Kushner Ph.D. | Co-Founder & Sr. Research Fellow |
| Ms. Courtney Dugan | VP of Investor Relations & Communications |
| Mr. John B. Moriarty Jr. | Exec. VP, Chief Legal Officer & Corp. Sec. |
| Ms. Julie Dexter | VP & Head of People |
| Dr. David C. Myles Ph.D. | Chief Discovery & Non-Clinical Devel. Officer |
| Ms. Demiana Faltaos Ph.D., Pharm.D. | VP & Head of Clinical Pharmacology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4534 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-11-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |